Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target of $12.00. The company’s shares closed yesterday at $4.55.
According to TipRanks, McCarthy is an analyst with an average return of -38.8% and a 14.29% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Actinium Pharmaceuticals, and Daré Bioscience.
Currently, the analyst consensus on Capricor Therapeutics is a Strong Buy with an average price target of $15.00, representing a 229.67% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Capricor Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $7.11 million. In comparison, last year the company earned a revenue of $204.08 thousand and had a GAAP net loss of $4.75 million
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CAPR in relation to earlier this year. Earlier this month, Karen Krasney, the EVP & GC of CAPR bought 18,932.00 shares for a total of $26,315.48.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
Read More on CAPR:
